NutribandNTRB
NTRB
About: Nutriband Inc is engaged in the development of a portfolio of transdermal pharmaceutical products. AVERSA technology is the company's product that incorporates aversive agents to prevent the Abuse, Diversion, Misuse, and Accidental exposure of drugs with abuse potential specifically Opioids. The majority of the revenue is generated from the sale of goods that include consumer transdermal and coated products.
Employees: 3
0
Funds holding %
of 7,296 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
150% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 2
78% more capital invested
Capital invested by funds: $1.15M [Q4 2024] → $2.06M (+$901K) [Q1 2025]
23% more funds holding
Funds holding: 13 [Q4 2024] → 16 (+3) [Q1 2025]
0.81% more ownership
Funds ownership: 2.2% [Q4 2024] → 3.02% (+0.81%) [Q1 2025]
0% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 4
Research analyst outlook
We haven’t received any recent analyst ratings for NTRB.
Financial journalist opinion
Neutral
GlobeNewsWire
6 days ago
Nutriband Announces U.S. Patent Issued for Its Transdermal Abuse Deterrent Technology
Patent issuance expands United States patent coverage for AVERSA™ transdermal abuse deterrent technology AVERSA™ transdermal abuse deterrent technology is protected by a broad international intellectual property portfolio with patents issued in 46 countries including the United States, Europe, Japan, Korea, Russia, China, Canada, Mexico, and Australia. ORLANDO, Fla.
Negative
Zacks Investment Research
2 weeks ago
Nutriband Inc. (NTRB) Reports Q1 Loss, Misses Revenue Estimates
Nutriband Inc. (NTRB) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to loss of $0.21 per share a year ago.
Neutral
GlobeNewsWire
1 month ago
Nutriband CEO Publishes Letter to Shareholders
ORLANDO, Fla., April 30, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW) today announced that CEO Gareth Sheridan has published a letter to shareholders providing insights on achievements and milestones through 2024 and the potential outlook for 2025.
Neutral
GlobeNewsWire
2 months ago
Nutriband Granted Patent in Macao for its AVERSA Abuse Deterrent Transdermal Technology
ORLANDO, Fla., April 11, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a company engaged in the development of prescription transdermal pharmaceutical products, today announced that it has received notification that its patent has been granted in Macao for its patent entitled, "Abuse and Misuse Deterrent Transdermal Systems," which protects its AVERSA™ abuse deterrent transdermal technology.
Neutral
GlobeNewsWire
2 months ago
UPDATE – Nutriband Signs Associate Partnership with Charlotte FC
ORLANDO, Fla., April 04, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (the “Company”)(NASDAQ:NTRB)(NASDAQ:NTRBW), a developer of transdermal pharmaceutical products, today announced that it has signed an Associate Partnership agreement with Charlotte FC.
Neutral
GlobeNewsWire
2 months ago
Nutriband Signs Partnership Agreement with Charlotte FC
ORLANDO, Fla., April 04, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (the “Company”)(NASDAQ:NTRB)(NASDAQ:NTRBW), a developer of transdermal pharmaceutical products, today announced that it has signed an Associate Partnership agreement with Charlotte FC.
Neutral
GlobeNewsWire
3 months ago
Nutriband Receives Certificate of Registration for Trademark covering Pharmaceutical and Product Research and Development.
ORLANDO, Fla., Feb. 21, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ: NTRB) (NASDAQ:NTRBW), a developer of transdermal pharmaceutical products, today announced that it received the Certificate of Registration from the United States Patent and Trademark Office (USPTO) on Feb 18, 2025, for trademark registration Number 7,692,920, covering the mark "Nutriband™.
Neutral
GlobeNewsWire
4 months ago
Nutriband and Kindeva Drug Delivery Formalize Exclusive Development Partnership for Aversa™ Fentanyl Abuse Deterrent Fentanyl Patch
Nutriband and Kindeva formalize exclusive product development partnership and long-term commitment based on shared development costs in exchange for milestone payments Nutriband is partnering with Kindeva Drug Delivery to develop Aversa™ Fentanyl which combines Nutriband's Aversa™ abuse-deterrent technology with Kindeva's FDA-approved fentanyl patch. ORLANDO, Fla.
Neutral
GlobeNewsWire
4 months ago
Nutriband Receives Notice Of Allowance For New U.S. Patent Covering Its Transdermal Abuse Deterrent Technology Aversa™
ORLANDO, Fla., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a company engaged in the development of prescription transdermal pharmaceutical products, today announced that it received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) on February 3, 2025 for patent application 18/369,241, "Abuse and Misuse Deterrent Transdermal Systems" which covers its Aversa™ abuse deterrent technology.
Neutral
GlobeNewsWire
5 months ago
Nutriband Issues Letter to Shareholders
ORLANDO, Fla., Dec. 31, 2024 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ: NTRB) (NASDAQ: NTRBW) today announced that CEO Gareth Sheridan has published a letter to shareholders highlighting the company's achievements in 2024 and the outlook for 2025.
Charts implemented using Lightweight Charts™